@article{APS11400,
author = {Zhi-chao Zhang and Ying Shen and Yu-shen Lin and Bo Yang and Ji Cao and Jun Li and Wen-bin Zhao},
title = {Peptide-MHC I regulatory mechanisms and intervention strategies in anti-tumor T cell immunity},
journal = {Acta Pharmacologica Sinica},
volume = {46},
number = {12},
year = {2025},
keywords = {},
abstract = {T cell immune responses are triggered by antigenic peptides presented through major histocompatibility complex class Is (pMHC-Is), which play an important role in the genesis, development, and therapy of tumors. The capacity of a specific pMHC-I to elicit T cell responses is deeply influenced by its expression level (quantity) and its immunogenicity (quality). Tumor cells can evade T cell immunity by down-regulating the quantity of pMHC-Is or selectively eliminating highly immunogenic antigenic peptides. Augmenting the quantity or quality of pMHC-Is is essential for tumor immunotherapy. However, the complexity of pMHC-I regulation and tumor heterogeneity pose challenges to clinical strategies. Consequently, developing approaches grounded in comprehensive analyses of pMHC-I regulatory mechanisms remains a focal point in the research of T cell immunity. In this review, we discuss how tumors modulate their surface pMHC-Is through genetic, epigenetic, and proteomic mechanisms and summarize potential therapeutic strategies targeting these mechanisms, which may provide a valuable reference for the development of novel tumor immunotherapies based on pMHC-I modulation.},
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/11400}
}